Composition for alleviating hair loss and promoting hair growth, comprising heat-treated lactic acid bacteria limosilactobacillus fermentum LM1020
The use of heat-treated lactic acid bacterium Rimosylactobacillus Fermentum LM1020 in a composition addresses the limitations of current hair loss treatments by promoting dermal papilla cell proliferation and hair growth, providing a safer and more effective solution for preventing hair loss.
Patent Information
- Application Number
- PCT/KR2023/016535
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2023-10-24
- Publication Date
- 2024-11-28
AI Technical Summary
Current hair loss treatments, such as Minoxidil and Propecia, have significant side effects and are not suitable for all demographics, highlighting the need for a more effective and safer solution that promotes hair growth and prevents hair loss.
A composition containing heat-treated lactic acid bacterium Rimosylactobacillus Fermentum LM1020, which promotes the proliferation of dermal papilla cells, exhibits 5α-reductase-1 inhibitory activity, and increases the expression of growth factors like FGF7, FGF10, and EGF, thereby preventing hair loss and promoting hair growth.
The composition effectively promotes hair papilla cell proliferation and growth, reduces hair loss, and enhances scalp microbiome diversity, offering a safer and more effective alternative to existing treatments.
Smart Images

Figure KR2023016535_28112024_PF_FP_ABST
Abstract
Description
Composition for alleviating hair loss and promoting hair growth comprising heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020
[0001] The present invention relates to heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, which has hair loss prevention and hair growth promotion effects, and more specifically, to heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, which has hair loss prevention and hair growth promotion effects by promoting the proliferation of hair follicle papilla cells, and to a composition comprising the same.
[0002] Hair loss refers to the absence of hair in areas where hair normally grows, typically resulting in the loss of terminal hair on the scalp. While hair loss was once considered a male-only problem, in modern society, the number of women struggling with hair loss is increasing, and the age at which it occurs is also gradually decreasing. This increase in the number of hair loss patients is garnering attention, leading to increased research into the causes, treatment options, and treatments of hair loss.
[0003] Currently, the most effective medications for preventing or treating hair loss include minoxidil and Propecia. However, minoxidil affects body hair, causing it to grow thicker and darker. Because minoxidil lowers blood pressure, those with low blood pressure should avoid its use. Because the drug is metabolized by the liver, those with liver problems should also avoid its use. Furthermore, Propecia is an androgen, so it is contraindicated for women. Side effects include loss of libido and sexual dysfunction. Recently, depression and mood swings have been reported in patients taking it, leading to additional precautions. Therefore, the development of a hair loss treatment that is more effective and has fewer side effects than minoxidil and Propecia is urgently needed.
[0004] Meanwhile, microbial resources, unlike oil and water, are classified as sustainable resources because they can be reproduced. They also have high potential for research and industrial application because they utilize the unique characteristics of microorganisms that have adapted to various environments. In particular, strain-derived components that have been inactivated through heat treatment or other methods but still offer health benefits are called postbiotics. Postbiotics possess functional properties such as immune regulation, skin condition improvement, antioxidant properties, and inflammation control. Because they are inactivated, they offer advantages over probiotics in terms of stability, safety, cost-effectiveness, and storability.
[0005] The skin surface and hair follicle openings are known to harbor a rich microbial community and exhibit robust immune activation. A strong correlation exists between immune specialties essential for the hair cycle and the microbial community. Changes in the hair follicle microbiome or the absorption of microbial metabolites are linked to inflammatory responses in the hair follicle, including the regulation of skin immune responses and homeostasis. As relief of follicular inflammation increases the likelihood of hair regrowth, managing the local scalp microbiome is crucial for hair loss and hair growth.
[0006] Accordingly, products are being developed to prevent hair loss, promote hair growth / growth, and enhance hair growth / growth for the recently rapidly increasing number of hair loss patients by utilizing microorganisms. For example, there is Republic of Korea Patent Publication No. 10-2017-0038462, but research on the exact mechanism of hair growth control by hair papilla cells or new regulatory substances is still insufficient.
[0007] Accordingly, the inventors of the present invention conducted research on a composition for preventing hair loss or promoting hair growth that can promote the proliferation of human dermal papilla cells (hDPCs), and as a result, confirmed that heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 (KCCM12918P) promotes the proliferation of human dermal papilla cells, thereby completing the present invention.
[0008] The present invention provides a composition comprising heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) having hair loss prevention and hair growth promotion effects.
[0009] However, the problems that the present invention seeks to solve are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.
[0010] The first aspect of the present invention provides a cosmetic composition for the proliferation of breast papilla cells, which comprises heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
[0011] The second aspect of the present invention provides a food composition for proliferation of breast papilla cells, which includes heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
[0012] The third aspect of the present invention provides a pharmaceutical composition for treating hair loss, which comprises heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
[0013] The heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 of this invention and the composition containing it promote the proliferation of hair follicle cells, have excellent 5α-reductase-1 inhibitory activity, and promote the expression of growth factors FGF7, FGF10, and EGF, thereby having the effect of preventing hair loss and promoting hair growth.
[0014] Figure 1 is a drawing showing the results of comparing the effects of heat-treated lactic acid bacteria on promoting the proliferation of mammary papilla cells.
[0015] Figure 2 is a drawing showing the results of comparing the effects of heat-treated lactic acid bacteria on promoting the growth of mammary papilla cells.
[0016] Figure 3 is a diagram showing the results of comparing the effect of heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 on the proliferation of mammary papilla cells according to concentration.
[0017] Figure 4a is a diagram showing the change in CDK2 expression level in breast papilla cells after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0018] Figure 4b is a diagram showing the change in CDK4 expression level in mammary papilla cells after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0019] Figure 4c is a diagram showing the change in CDK6 expression level in mammary papilla cells after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0020] Figure 4d is a diagram showing changes in the expression level of cyclin B1 in breast papilla cells after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0021] Figure 4e is a diagram showing changes in the expression level of cyclin D1 in mammary papilla cells after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0022] Figure 4f is a diagram showing changes in the expression level of cyclin E1 in breast papilla cells after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0023] Figure 5a is a diagram showing the results of confirming the expression level of the 5α-reductase gene of the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 in human scalp tissue.
[0024] Figure 5b is a diagram showing the results of confirming the expression level of the FGF7 (Fibroblast growth factor 7, type 7 fibroblast growth factor) gene of heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 in human scalp tissue.
[0025] Figure 5c is a drawing showing the results of confirming the expression level of FGF10 (Fibroblast growth factor 10, type 10 fibroblast growth factor) gene of heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 in human scalp tissue.
[0026] Figure 5d is a diagram showing the results of confirming the expression level of the EGF (Epidermal Growth Factor) gene of the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 in human scalp tissue.
[0027] Figure 6 is a drawing showing the results of comparing the growth-promoting effects of L-menthol, salicylic acid, dexpanthenol and a mixture thereof (LSD), heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 and a heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 and a complex of L-menthol, salicylic acid and dexpanthenol on hair follicle cell growth.
[0028] Figure 7a is a diagram showing the change in the ratio of Staphylococcus and Lactic acid bacteria (Operational Taxonomy unit) in the scalp of participants before and after using a product containing heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020.
[0029] Figure 7b is a graph showing the change in the Shannon index for the entire microbiome of Staphylococcus and Lactic Acid Bacteria in the scalp of participants before and after using a product containing heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020.
[0030] Figure 7c is a graph showing the change in the Shannon index for total lactic acid bacteria (LAB) of Staphylococcus and lactic acid bacteria in the scalp of participants before and after using a product containing heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020.
[0031] Figure 7d is a diagram showing changes in the major microorganisms on the scalp of participants before and after using a product containing heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0032] Figure 7e is a diagram showing changes in the major microorganisms on the scalp of participants before and after using a product containing heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020.
[0033] Below, with reference to the attached drawings, embodiments of the present invention are described in detail to facilitate easy implementation by those skilled in the art. However, the present invention can be implemented in various different forms and is not limited to the embodiments described herein. In the drawings, irrelevant parts have been omitted for clarity, and similar reference numerals have been used throughout the specification to indicate similar elements.
[0034] Throughout this specification, when it is said that an element is “on” another element, this includes not only cases where the element is in contact with the other element, but also cases where another element exists between the two elements.
[0035] Throughout this specification, when a part is said to “include” a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise specifically stated. The terms “about,” “substantially,” etc., used throughout this specification, are used in a sense of numerical value or approximation when manufacturing and material tolerances inherent to the meanings referred to are presented, and are used to prevent unscrupulous infringers from unfairly exploiting disclosures that contain precise or absolute values to aid understanding of this specification. The terms “step of doing” or “step of” used throughout this specification do not mean “step for.”
[0036] Throughout this specification, the term “combination(s) thereof” included in the expressions in the Makushi format means one or more mixtures or combinations selected from the group consisting of the components described in the expressions in the Makushi format, and means including one or more selected from the group consisting of said components.
[0037] Throughout this specification, references to “A and / or B” mean “A or B, or A and B.”
[0038] Hereinafter, implementation examples and embodiments of the present invention will be described in detail with reference to the attached drawings. However, the present invention may not be limited to these implementation examples and embodiments and drawings.
[0039] The first aspect of the present invention provides a cosmetic composition for the proliferation of breast papilla cells, which comprises heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
[0040] The term "heat-treated lactic acid bacteria" used throughout this specification refers to dead cells of the strain Rimosylactobacillus fermentum LM1020 that have been inactivated by heat treatment.
[0041] The term "killed cells" used throughout this specification is the opposite of live cells, and refers to a form in which live cells and metabolites obtained through fermentation have been heat-treated or otherwise rendered ineffective in preventing bacterial growth. Killed cells may contain cytoplasm, cell walls, antimicrobial substances such as bacteriocins, polysaccharides, organic acids, etc. Products using the killed cells have a higher stability compared to live cell products, and in particular, have excellent heat resistance and high stability against the external environment, making them easier to store and have a longer shelf life than existing live cell products. In addition, as regulations on the use of antibiotics are strengthened, their usability as an alternative and the fact that only a few companies have fully entered the production of killed cell products have made them very promising in terms of marketability and growth potential.
[0042] In one embodiment of the present invention, the component derived from the strain Rimosylactobacillus fermentum LM1020 may be derived from fermented dough, but is not limited thereto.
[0043] In one embodiment of the present invention, the heat-treated lactic acid bacterium Rimosyl Lactobacillus fermentum LM 1020 may have a ratio of saturated fatty acid: unsaturated fatty acid: cyclic fatty acid of 0.1 to 2: 0.25 to 5: 0.03 to 0.6, preferably 1:2.5:0.3, but is not limited thereto.
[0044] In one embodiment of the present invention, the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM 1020 may increase the expression of CDK2, CDK4, cyclin B1, and cyclin D1.
[0045] In one embodiment of the present invention, the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM 1020 may reduce the expression amount of the 5α-reductase-1 gene and increase the expression amounts of the FGF7, FGF10, and EGF genes.
[0046] In one embodiment of the present invention, the cosmetic composition for proliferation of breast papilla cells may additionally contain L-menthol, salicylic acid, and dexpanthenol.
[0047] In one embodiment of the present invention, when the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 of the present invention and the complex of L-menthol, salicylic acid and dexpanthenol were treated together, the growth promotion effect of hair papilla cells was superior to when the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 was used alone.
[0048] In one embodiment of the present invention, the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM 1020 is 1×10 4 cells / mL to 1×10 8 It can be cell / mL, preferably 1×10 6 cells / mL to 1×10 7 It can be cell / mL, more preferably 1×10 6 cell / mL or 1×10 7 It can be, but is not limited to, cells / mL.
[0049] In one embodiment of the present invention, the cosmetic composition for proliferation of hair follicle cells may further include purified water, ethanol, Alanine / Histidine / Lysine Polypeptide Copper HCl, polyacrylate crosspolymer-6, coconut acid, proline, tea tree oil, glycerin, peptide, butylene glycol, 1,2-hexanediol, green tea extract, lavender flower extract, quince extract, and ethylhexanediol, and the cosmetic composition for proliferation of hair follicle cells may increase the diversity of microorganisms and lactic acid bacteria of the scalp.
[0050] The second aspect of the present invention provides a food composition for the proliferation of breast papilla cells, comprising heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient. Any content overlapping with the first aspect of the present invention also applies to the food composition of the second aspect of the present invention.
[0051] The term "food" as used throughout this specification includes meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, health functional foods, and health foods, and includes all foods in the conventional sense.
[0052] The term "health functional food" used throughout this specification refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body as defined in Act No. 6727 on Health Functional Foods, and "functionality" means obtaining a beneficial effect for health purposes, such as regulating nutrients or physiological effects on the structure and function of the human body.
[0053] The food of the present invention can be manufactured by methods commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art during the manufacturing process. In addition, the food formulation can be manufactured without limitation as long as it is a formulation recognized as a food. The food composition of the present invention can be manufactured in various forms of formulation, and unlike general drugs, it has the advantage of not having side effects that may occur with long-term use of drugs because it uses food as a raw material, and is highly portable, so the food of the present invention can be consumed as a supplement to enhance the effect of improving the intestinal environment.
[0054] The above health food refers to a food that has a more active health maintenance or promotion effect than general food, and health supplement food refers to a food for the purpose of health supplementation. In some cases, the terms health functional food, health food, and health supplement may be used interchangeably. Specifically, the health functional food refers to a food that is prepared by adding the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 of this disclosure to food materials such as beverages, teas, spices, gums, and confectioneries, or by manufacturing it in the form of encapsulation, powder, suspension, etc., and means that when consumed, it brings about a specific health effect. However, unlike general drugs, it has the advantage of not having side effects that may occur with long-term use of drugs because it is made from food as a raw material.
[0055] The food composition of this hospital can be consumed on a daily basis, so it can be expected to be highly effective in improving depression, and thus can be used very usefully.
[0056] The above food composition may additionally include a physiologically acceptable carrier. The type of the carrier is not particularly limited, and any carrier commonly used in the art may be used.
[0057] In addition, the food composition may include additional ingredients commonly used in food compositions to improve odor, taste, sight, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr), etc. In addition, it may include amino acids such as lysine, tryptophan, cysteine, and valine.
[0058] In addition, the food composition may include food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), sterilizers (bleaching powder and high-purity bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar colorants, etc.), color developers (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, D-potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (glucose fillers), film-forming agents, gum-forming agents, foam suppressants, solvents, and improvers. The above additives can be selected according to the type of food and used in an appropriate amount.
[0059] The heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 of this invention can be added as is or used together with other foods or food ingredients, and can be used appropriately according to a conventional method. The mixing amount of the active ingredient can be appropriately determined depending on its purpose of use (prevention, health, or therapeutic treatment). Generally, when manufacturing a food or beverage, the food composition of the present invention can be added to the food or beverage in an amount of 50 parts by weight or less, specifically 20 parts by weight or less. However, when consumed for a long period of time for health and hygiene purposes, the content below the above range can be included, and since there is no problem in terms of safety, the active ingredient can be used in an amount above the above range.
[0060] As an example, the food composition of the present invention can be used as a health beverage composition, and in this case, it can contain various flavoring agents or natural carbohydrates as additional ingredients like a regular beverage. The above-mentioned natural carbohydrates can be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; sugar alcohols such as xylitol, sorbitol, and erythritol. The sweetener can be a natural sweetener such as thaumatin and stevia extract; a synthetic sweetener such as saccharin and aspartame, etc. The proportion of the natural carbohydrate can be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the health beverage composition of the present invention.
[0061] In addition to the above, the health beverage composition may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, or carbonating agents. In addition, it may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, or vegetable drinks. These ingredients may be used independently or in combination. The proportion of these additives is not particularly important, but is typically selected within the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
[0062] The food composition of the present invention may contain the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 of the present invention in various weight % if it can exhibit hair loss prevention and hair growth promotion effects, and specifically, the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 of the present invention may be contained in an amount of 0.00001 to 100 weight % or 0.01 to 80 weight % relative to the total weight of the food composition, but is not limited thereto.
[0063] In one embodiment of the present invention, the food composition may be a health functional food composition.
[0064] The third aspect of the present invention provides a pharmaceutical composition for treating hair loss, comprising heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient. Any content overlapping with the first and second aspects also applies to the pharmaceutical composition of the third aspect of the present invention.
[0065] In one embodiment of the present invention, the pharmaceutical composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions, according to conventional methods, but may not be limited thereto.
[0066] In one embodiment of the present invention, when formulating the pharmaceutical composition, it may be prepared using a diluent or excipient such as a generally used filler, bulking agent, binder, wetting agent, disintegrant, or surfactant, but may not be limited thereto.
[0067] In one embodiment of the present invention, solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations may be prepared by mixing the strain-derived component with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, or gelatin. In addition, for example, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used, but may not be limited thereto.
[0068] In one embodiment of the present invention, liquid preparations for oral administration include suspensions, solutions, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included, but may not be limited thereto.
[0069] In one embodiment of the present invention, formulations for parenteral administration may include, but are not limited to, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. For example, non-aqueous solvents or suspensions may include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. For example, suppositories may include, but are not limited to, witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin.
[0070] A pharmaceutical composition according to one embodiment of the present invention may be a pharmaceutical composition or a quasi-drug composition.
[0071] The term "quasi-drug" used throughout this specification refers to products that are used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases in humans or animals, and have a milder effect than drugs. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are products other than those used for the purpose of drugs, and include products used for the treatment or prevention of diseases in humans or animals, and products that have a mild effect on the human body or do not directly affect it.
[0072] The above-mentioned pharmaceutical composition of the present invention can be manufactured in a formulation selected from the group consisting of body cleanser, disinfectant, detergent, kitchen detergent, cleaning detergent, toothpaste, mouthwash, wet tissue, detergent, soap, hand wash, hair cleanser, hair softener, humidifier filler, mask, ointment, and filter filler, but is not limited thereto.
[0073] In one embodiment of the present invention, the pharmaceutical composition may be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" herein means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention, and the effective dosage level may be determined according to factors including the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the excretion rate, the treatment period, drugs used in combination or simultaneously with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered alone or in combination with a component known to exhibit a therapeutic effect on a known intestinal disease. It is important to take all of the above factors into consideration and administer an amount that can achieve the maximum effect with the minimum amount without side effects.
[0074] In one embodiment of the present invention, the dosage of the pharmaceutical composition may be determined by a person skilled in the art in consideration of the purpose of use, the degree of toxicity of the disease, the patient's age, weight, sex, medical history, or the type of substance used as the active ingredient. For example, the pharmaceutical composition of the present invention may be administered at about 0.1 ng to about 1,000 mg / kg, preferably 1 ng to about 100 mg / kg, per adult, and the frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or administered in divided doses several times. The dosage or frequency of administration does not limit the scope of the present invention in any way.
[0075] The pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered via routes such as intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, transdermal patch administration, oral administration, intranasal administration, intrapulmonary administration, and rectal administration depending on the intended purpose. However, when administered orally, it may be administered in an unformulated form, and since the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 may be denatured or decomposed by gastric acid, the oral composition may be administered orally in a form that coats the active agent or is formulated to protect it from decomposition in the stomach, or in the form of an oral patch. In addition, the composition may be administered by any device that allows the active agent to move to the target cell.
[0076] Hereinafter, the present invention will be described in more detail through examples of the present invention. However, the following examples are provided only to help understanding of the present invention, and the contents of the present invention are not limited to the following examples.
[0077] [Example]
[0078] Example 1. Comparison of the effects of heat-treated lactic acid bacteria on the proliferation of mammary papilla cells.
[0079] The mammary papilla cells were purchased from PromoCell and were 5000-10000 cells / cm 2 The cells were seeded in flasks at a density of 10 μg / mL and cultured. The dermal papilla cells were cultured in a dermal papilla cell culture medium prepared by adding growth factors (40 μL / mL fetal calf serum, 4 μL / mL bovine pituitary extract, 1 ng / mL fibroblast growth factor, 5 μg / mL insulin) to a commercial basal medium, and cultured at 37°C with 5% CO2 concentration. The dermal papilla cells were subcultured and used for experiments when they reached 80-90% confluency. The dermal papilla cells used in the study were stored in liquid nitrogen for 2-5 generations, and up to 10 generations were used in the experiments.
[0080] The effect of heat-treated lactic acid bacteria on the proliferation of mammary papilla cells was confirmed by observing viable cells under a microscope through trypan blue staining. Mammary papilla cells that reached 80-90% confluency were inoculated into a 24-well plate at a concentration of 100,000 cells / well and cultured for 24 hours, and then 1Х10 7 The number of cells increased compared to the control group was directly counted using a microscope after treatment with heat-treated lactic acid bacteria at a concentration of cell / mL. The heat-treated lactic acid bacteria used to compare the effects of promoting proliferation of breast papilla cells were Lactobacillus plantarum LP1001, Lactococcus lactis LP1009, Lacticazeibacillus rhamnosus LP1011, Lacticazeibacillus paracasei LP1014, Bifidobacterium animalis lactis LP1017, Rimosylactobacillus fermentum LP1016, Rimosylactobacillus fermentum LM1020, Lactobacillus acidophilus LP1060, and Lactobacillus gasseri LP1065.
[0081] The comparative results showed that not all heat-treated lactic acid bacteria promoted the proliferation of hair papilla cells. Among the nine types of heat-treated lactic acid bacteria, only Lactobacillus paracasei LP1014, Lactobacillus acidophilus LP1060, Rimosylactobacillus fermentum LP1016, and Rimosylactobacillus fermentum LM1020 were able to promote the growth of hair papilla cells, while the other heat-treated lactic acid bacteria were confirmed to inhibit the growth of hair papilla cells (Fig. 1).
[0082] Although Rimosylactobacillus fermentum LP1016 and Rimosylactobacillus fermentum LM1020 are conspecific, LP 1016 originated from kimchi, while LM1020 originated from fermented dough, indicating a difference in the origins of each strain. As a result of the study, even when heat-treated using the same method, the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LP1016 derived from kimchi increased the proliferation of hair papilla cells by 3.7%, whereas the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 derived from fermented dough showed a significant difference, increasing the proliferation of hair papilla cells by 24.9%.
[0083] Example 2. Cell Fatty Acid Composition of Heat-Treated Lactic Acid Bacteria
[0084] Fungal fatty acids are known to play various roles in the fungus as precursors of intracellular membrane-bound organelles, including the cell membrane. The internal standard (ISTD) was selected as methyl undecanoate, which does not commonly exist in nature, and was prepared at a concentration of 10,000 μg / mL using HPLC-grade n-nucleic acid as a solvent. It was stored at -20°C and diluted as needed for use in the study. To extract fatty acids from heat-treated lactic acid bacteria, 25 μl of the internal standard was added, and 200 μl of a 2:1 (v / v) mixture of chloroform and methanol was added. Afterwards, 300 μl of a 0.6 M hydrochloric acid methanol solution was added to derivatize the fatty acids, followed by homogenization for 120 s, heating at 85°C for 60 min, and cooling to room temperature. After adding 1 mL of n-hexane again, homogenization was performed for 120 seconds, and the supernatant was left at room temperature for 60 to 120 minutes. The supernatant was used for analysis. Fatty acids were analyzed by gas chromatography / mass spectrometry electron ionization analysis, using helium as the mobile phase and a DB-FastFAME column as the column.
[0085] As a result, it was confirmed that the composition of the cell fatty acids of the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LP1016 and Rimosylactobacillus fermentum LM1020, which are of the same genus but have different strain origins, were different (Table 1). In particular, linoleate was present only in the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, and behenic acid was present only in the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LP1016. Among the fatty acids, oleate was present about 2.4 times more in the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, and lactobacillic acid was present about 2.1 times more in the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LP1016.
[0086] The two strains also differed significantly in the ratio of saturated and unsaturated fatty acids in their cells. While the kimchi-derived Rimosylactobacillus fermentum LP1016 had a saturated fatty acid:unsaturated fatty acid:cyclic fatty acid ratio of 1:1:0.6, the fermented dough-derived Rimosylactobacillus fermentum LM1020 had a ratio of 1:2.5:0.3, confirming that the composition of each fatty acid was different and that the characteristics of the overall fatty acids also showed significant differences.
[0087] Fatty AcidsContents a (%)LM1016LM1020Laurate0.710.49Myristate1.151.21Pentadecanoate0.420.46Palmitate32.4421.79Palmitoleate1.281.26Palmitelaidate1.341.37 Margarate0.000.00Stearate3.372.08Oleate8.7320.62cis-11-Vaccenate21.233.34Linoleate0.001.07cis-10-nonadecenoate9.088.54Lactobacillic acid16.547.77Arachidate0.000.00cis-11,14-Eicosadienoate0.000.00Behenic acid 1.200.00 saturated fatty acid 40.3126.03 unsaturated fatty acid 43.1466.20 cyclic fatty acid 25.697.77 unsaturated fatty acid / saturated fatty acid 1.072.54 unsaturated fatty acid + cyclic fatty acid / saturated fatty acid 1.482.84
[0088] Example 3. Comparison of the growth-promoting effects of heat-treated lactic acid bacteria on mammary papilla cells.
[0089] The effect of heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 on hair follicle cell proliferation was verified through comparison with strains (Lacticazeibacillus paracasei KCTC 14004BP and Rimosylactobacillus fermentum KCCM 11910P) known to be effective in preventing hair loss, promoting hair growth, or promoting hair growth (Fig. 2).
[0090] All strains used for comparison were inactivated by heat treatment at a high temperature of 121°C for 15 minutes.
[0091] 2.5×10 in mammary papilla cells (10,000 cells / well) 7 After treating with heat-treated lactic acid bacteria at a concentration of 1 cell / mL, the cells were cultured as in Example 1, and the effect of promoting the growth of mammary papilla cells was calculated using the formula below.
[0092] The growth rate when only hair papilla cells were cultured was compared with the growth rate when heat-treated lactic acid bacteria were added to confirm the growth promotion effect of heat-treated lactic acid bacteria on hair papilla cells. The growth rate when hair papilla cells were cultured using the above method without adding anything was calculated compared to the growth rate when heat-treated lactic acid bacteria Lacticazeibacillus paracasei KCTC 14004BP, heat-treated lactic acid bacteria Rimosylactobacillus fermentum KCCM 11910P, and heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 were added, and the growth promotion effect of heat-treated lactic acid bacteria on hair papilla cells was calculated using the formula below and compared. All tests were performed in triplicate, and the average of each result was calculated and compared.
[0093] Growth promotion effect of mammary papilla cells (%) = (BA)÷A×100
[0094] A = Growth rate of mammary papilla cells in the untreated group
[0095] B = Growth rate of mammary papilla cells when treated with heat-treated lactic acid bacteria
[0096] As a result, 2.5×10 7 At a concentration of cell / mL, heat-treated lactic acid bacteria Rimosylactobacillus fermentum KCCM11910P inhibited the growth of breast papilla cells, and heat-treated lactic acid bacteria Lacticazeibacillus paracasei KCTC14004BP promoted the growth of breast papilla cells, but showed a cell growth rate more than twice lower than that of heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 of the present invention.
[0097] Example 4. Effect of heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 on the proliferation of mammary papilla cells at different concentrations.
[0098] In Examples 1 and 2, the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, which showed the best growth-promoting effect on dermal papilla cells, was tested to determine whether it could promote the proliferation of dermal papilla cells even in a growth factor-deficient environment. Dermal papilla cells were inoculated into a 96-well plate and cultured for 24 hours. The medium in the well was replaced with a medium lacking growth factors and cultured for an additional 24 hours. Afterwards, the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 was added at various concentrations, and whether the growth of dermal papilla cells was promoted after 24 hours was confirmed. The growth-promoting effect on dermal papilla cells was confirmed by adding 0.5 mg / mL of thiazolyl Blue tetrazolium bromide (MTT) and culturing at 37°C, dissolving the formazan produced in DMSO, and measuring the absorbance at 570 nm.
[0099] As a result, heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 was able to proliferate mammary papilla cells even under culture conditions lacking mammary papilla cell growth factors, and 1×10 3 cell / mL ~ 1×10 5 In the cell / mL concentration range, the growth of mammary papilla cells increased in a concentration-dependent manner, and 1×10 6 At high concentrations of cells / mL or more, the proliferation effect of mammary papilla cells showed a similar trend regardless of concentration. The effect of promoting mammary papilla cell proliferation was 1×10 7 It was the best in cells / mL, and a proliferation promotion effect of 156% was confirmed compared to the untreated group (Fig. 3).
[0100] Example 5. Increased expression of proteins related to proliferation of mammary papilla cells.
[0101] In order to confirm the mechanism of action of heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, which showed the best effect in promoting the growth of breast papilla cells in Examples 1 and 2, in promoting the proliferation of breast papilla cells, the expression level of proteins related to the proliferation of breast papilla cells was measured.
[0102] Dermal papilla cells are fibroblasts derived from the mesoderm, and their proliferation is regulated by cell cycle proteins such as cyclins, CDKs (cyclin-dependent kinases), and CDK inhibitors. The cells exist in either a resting or proliferative phase, and growing cells undergo a cell cycle that includes the G1 phase, the S phase (DNA synthesis phase), the G2 phase, and the M phase (mitosis), ultimately dividing into two cyst cells and proliferating.
[0103] CDK2 (Cyclin-dependent kinase 2) is a kinase involved in cell cycle regulation and is essential for meiosis but not mitosis. It regulates the activation of cyclin BCDK1 by controlling the subsequent activation of cyclin B / CDK1 through phosphorylation, thereby controlling the timing of entry into mitosis and meiosis. CDK2 activity is maximal in the S and G2 phases of cell division. CDK4 (Cyclin-dependent kinase 4) is required for the transition from G1 to S phase of the cell cycle. CDK6 (Cyclin-dependent kinase 6) promotes the G1 / S transition and is involved in the initiation and maintenance of the cell cycle during cell differentiation. Its main function is to prevent cell proliferation and regulate negative cell differentiation. Cyclin B1 is a regulatory protein involved in mitosis and is a cell cycle regulatory transcript expressed during the G2 / M phase of the cell cycle.
[0104] Cyclin B1 plays a role in determining whether cells will enter mitosis, and upon activation, it forms a cyclin B1-CDK1 complex, which promotes early mitosis through various mechanisms.
[0105] Cyclin D1 is one of the target genes of the Wnt / β-catenin signaling pathway, which plays an important role in processes such as hair growth, stem cell regulation, and cell proliferation, and affects cell division throughout the cell division cycle of hair papilla cells.
[0106] Cyclin E1 can induce the early G1 phase of the cell division cycle in hair papilla cells. Cyclin E1 promotes the transition from G1 to S phase, thereby inducing the initiation of DNA synthesis. Cyclin E1 is maximally expressed during the G1 / S phase of the cell cycle.
[0107] To measure the protein expression level of mammary papilla cells, 4 × 10 mammary papilla cells were seeded in a 6-well microplate. 5 After injection at a concentration of 10 cells / mL, the cells were cultured for 24 hours, and then the culture medium was replaced with a basic medium (a medium without growth factors for breast papilla cells such as insulin) and cultured for an additional 24 hours. Afterwards, heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 was added at various concentrations (final concentration: heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 1×10 6 , 1×10 7 and 1×10 8 The culture medium for mammary papilla cells was replaced with a medium treated with 100% (cell / mL), and the proliferation of mammary papilla cells was induced by co-culturing the mammary papilla cells with the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 at different concentrations for 24 hours, and after the culture was completed, Pro-Prep TMProteins from hair follicle cells were extracted using lysis buffer (Intron, Korea). The amount of extracted proteins was measured using the BCA protein assay, and protein expression levels were measured by Western blotting using the Protein Simple Jess system (Jess; Protein Simple, USA). Electrophoresis, blocking, primary antibody reaction, and secondary antibody reaction were performed inside the capillary using the Jess capillary cartridge, and the expression level was confirmed using the ECL detection reagent.
[0108] As a result, it was confirmed that heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 increases the expression of cyclin and CDK proteins, which are proteins necessary for the growth cycle of dermal papilla cells, thereby promoting the growth of dermal papilla cells (Figs. 4a to 4f). The degree of protein expression affecting the proliferation of dermal papilla cells varied depending on the treatment concentration of heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020, but the expression of CDK2, CDK4, cyclin B1, and cyclin D1 tended to increase, while CDK6 and cyclin E1 tended to decrease (Table 2).
[0109] In particular, heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 increased cyclin B1 expression by up to 3.9 times (Fig. 4d), which means that during the same growth time, the number of cells that reached the G2 / M phase of the cell division cycle of hair papilla cells was greater than that of the control group (untreated), and the number of hair papilla cells dividing after DNA replication was greater.
[0110] In addition, when heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 was treated, the expression of cyclin D1 protein, which affects cell division throughout the cell division cycle of hair papilla cells, increased by up to 2.4 times (Fig. 4e). This means that heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 formed a cyclin D1-CDK4 complex in hair papilla cells, induced the transition from the G1 phase of cell division to the S phase where DNA is replicated, and promoted the growth of hair papilla cells.
[0111] Meanwhile, after treatment with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020, the expression levels of cyclin E and CDK6, which induce the early G1 phase of the cell division cycle of hair papilla cells, were slightly reduced or maintained at a similar level to before treatment (Fig. 4c, Fig. 4f). This means that hair papilla cells treated with heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 passed the G1 phase, the early stage of the cell division cycle, and reached more G2 / M phases.
[0112] Increase in protein expression of L. fermentum LM1016 treated group compared to control group CDK2CDK4CDK6Cyclin B1Cyclin D1Cyclin E11×10 6 cell / mL1.38 times1.40 times0.74 times2.63 times1.88 times0.83 times1×10 7 cell / mL1.16 times2.07 times0.91 times3.83 times2.43 times0.82 times1×10 7 cell / mL1.22 times1.56 times1.01 times3.85 times2.04 times1.16 times
[0113] Example 6. Measurement of hair loss prevention and hair growth effects using human-derived tissues.
[0114] 6-1) Explant tissue culture
[0115] Human scalp tissue provided for research purposes (IRB No. 4-2021-1524; Yonsei University College of Medicine, Severance Medical Center Institutional Review Board) was washed several times with PBS to remove residual impurities and prepared into 1 cm × 1 cm pieces.
[0116] Heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 was added to a scalp tissue-specific medium at 1×10 8 cells / mL or 1×10 9 After diluting to a concentration of 10 cells / mL, 50 μL was applied to human scalp tissue, and for the negative control group, 50 μL of scalp tissue-specific medium was applied instead of heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020. The medium was cultured at 37°C and 5% CO2, and the medium was replaced and the treatment material was applied at 24-hour intervals. After 72 hours of application, subcutaneous tissue, epidermis, and dermis were separated from each tissue and used for testing.
[0117] 6-2) Real-Time Polymerase Chain Reaction (RT-PCR)
[0118] The gene expression levels of hair loss and hair growth-related factors (5α-reductase-1, FGF7, FGF10, and EGF) were confirmed using real-time polymerase chain reaction. The gene expression level of 5α-reductase-1 was confirmed in subcutaneous tissue isolated from human scalp tissue, and the gene expression levels of FGF7, FGF10, and EGF were confirmed in epidermal and dermal tissues.
[0119] 5α-reductase-1, one of the hair loss-related factors, is mainly distributed in keratinocytes of hair papilla cells, sebaceous glands, epidermis, and hair follicles, and is an enzyme that acts with testosterone to produce DHT (Dihydrotestosterone), the main cause of hair loss. It is known that a decrease in 5α-reductase-1 gene expression in human hair papilla cells is involved in preventing hair loss (H Rastegar et al., 2015).
[0120] FGF7 (fibroblast growth factor type VII) is produced by fibroblasts and secreted into keratinocytes. It is a proliferation factor that promotes the proliferation of epithelial and epidermal cells, promotes hair follicle cell differentiation, induces proliferation of the vascular system of the dermal papilla, and increases the amount of extracellular matrix to maintain hair follicles in the growth phase. FGF10 (fibroblast growth factor type X) is known to be a factor that contributes to the initial formation of cells and promotes hair growth by inducing telogen hair follicles to the growth phase or proliferation phase (Sole Cho et al., 2016).
[0121] EGF is well known as a growth factor involved in hair follicle maturation, and has been studied to promote proliferation of hair papilla cells through activation of the Notch mechanism (Zhang et al., 2016).
[0122] The tissues for which the test was completed were pulverized using TissueLyser II (Qiagen), and total RNA was extracted using TRIzol Reagent (Invitrogen). The extracted total RNA was used to synthesize cDNA using RNA to cDNA EcoDryTM Premix (Oligo dT) (Clontech). Real-time polymerase chain reaction was performed using synthesized cDNA, Taqman Fast Advanced Master Mix (Applied Biosystems), and Taqman primers for each target (SRD5A1 (5-α-reductase-1): Hs00971645_g1, FGF7: Hs00940253_m1, FGF10: Hs00610298_m1, EGF: Hs01100002_m1; Applied Biosystems). Relative quantitative analysis of each gene was performed using the housekeeping gene GAPDH (Hs02786624_g1, Applied Biosystems).
[0123] During cDNA amplification, the amount of amplification can be checked in real time to obtain the threshold cycle (Cт) value, which is the intersection point between the amplification curve and the threshold line. Based on this value, the relative quantitation value (RQ) can be calculated to determine the relative mRNA expression level of the target gene. RQ is calculated using the following formula.
[0124] RQ = 2 -△△Cт
[0125] △△Cт = △Cт (treatment) - △Cт (control)
[0126] △Cт = Cт(target gene) - Cт(housekeeping gene)
[0127] - Treatment (experimental group): Test product treatment
[0128] - Control: Negative control group
[0129] - Target gene: SRD5A1 (5α-reductase-1), FGF7, FGF10, EGF
[0130] - Housekeeping gene: GAPDH
[0131] 6-3) Statistical analysis
[0132] Statistical analysis was performed using the IBM SPSS statistics 25.0 program, and the significance of the experimental and control groups was confirmed at a hypothesized mean difference of 5% (p<0.05). After the normality test, significance was confirmed using an independent-samples t-test (parametric method) depending on whether normality was satisfied.
[0133] 6-4) Research Results
[0134] 5α-reductase, known to be a cause of hair loss, was significantly reduced at all concentrations regardless of the concentration of heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 (p<0.05). FGF7, FGF10, and EGF, which induce hair growth, were significantly reduced in the high-concentration treatment group of 1×10 9 cells / mL was significantly increased (p<0.05). Therefore, it was confirmed that heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 can help prevent hair loss and promote hair growth.
[0135] Example 7. Hair loss prevention effect of functional raw materials and heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 that help alleviate hair loss symptoms
[0136] The effect of using L-menthol, salicylic acid, and dexpanthenol, which are frequently used active ingredients in functional cosmetics to help alleviate hair loss symptoms, together with heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, on the growth of dermal papilla cells was investigated. Dermal papilla cells were inoculated into 96-well plates and cultured for 24 hours. After that, the medium in the wells was replaced with medium lacking adult genes and cultured for an additional 24 hours. Thereafter, heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020, L-menthol, salicylic acid, and dexpanthenol were treated alone or in a mixture in a ratio of 3:2.6:2 to the dermal papilla cells prepared by the above method, and the effect on the growth of the dermal papilla cells was investigated.
[0137] The growth rates of breast papilla cells cultured alone and those of breast papilla cells treated alone or in combination with L-menthol, salicylic acid, dexpanthenol, and heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 were calculated, and the growth promoting effects of each treatment substance were calculated using the formula below and compared. All tests were performed three times, and the average of each result was calculated and compared.
[0138] Growth promotion effect of mammary papilla cells (%) = (BA)÷A×100
[0139] A = Growth rate of mammary papilla cells in the untreated group
[0140] B = Growth rate of hair follicle cells when treated with L-menthol, salicylic acid, dexpanthenol, and heat-treated Limosyl Lactobacillus LM1020
[0141] As a result, among L-menthol, salicylic acid, and dexpanthenol, which are widely known to have hair loss relief effects, L-menthol and salicylic acid were found to inhibit the growth of hair papilla cells. Dexpanthenol was able to promote the growth of hair papilla cells, but its growth-promoting effect was lower than that of the heat-treated lactic acid bacterium Rimosylactobacillus fermentum LM1020 at all concentrations. Meanwhile, it was confirmed that when the heat-treated lactic acid bacterium Rimosylactobacillus fermentum LM1020 was treated together with a complex of L-menthol, salicylic acid, and dexpanthenol, it could overcome the growth-inhibiting effect of the complex and promote the growth of hair papilla cells. In order to closely understand their synergistic effect, the effect predicted by the Colby formula was calculated, and the predicted value was compared with the measured value (measured value) to verify whether a synergistic effect exceeding the predicted value could be produced.
[0142] Colby formula
[0143] Predicted value = (A+B)-(A×B / 100)
[0144] (Source: SR Colby, "Calculating Synergistic and Antagonistic Responses of Herbicide Combinations", Weeds 1967, 15, 20-22)
[0145] As a result, a mixture of L-menthol, salicylic acid, and dexpanthenol in a ratio of 3:2.6:2 inhibited the growth of mammary papilla cells, but when the mixture was treated together with heat-treated lactic acid bacteria Rimosylactobacillus LM1020, the growth of mammary papilla cells was promoted. In addition, 1×10 of the mixture and heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 6 or 1×10 7 When treated with cell / mL, the effect of promoting mammary papilla cell growth was superior to that of using heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 alone.
[0146] Serial number Name of the growth promotion effect of mammary gland cells (%) Measurement value Predicted value 1) 1 Control group (no additives) 002 L-menthol - 12.05 ± 3.31 - 3 Salicylic acid - 0.39 ± 0.80 - 4 Dexpanthenol 2.35 ± 1.61 - 5 LSD (L-menthol: salicylic acid: dexpanthenol = 3:2.5:2 mixture) - 10.81 ± 1.17 - 6 LM1020_1 (heat-treated Limosyl Lactobacillus fermentum LM1004 dead cells 1 × 10 6 cell / mL)0.69±2.01-7LM1020_2 (heat-treated Limosyl Lactobacillus fermentum LM1004 dead cells 1×10 7 cell / mL)10.17±3.85-8LM1020_3(Heat-treated Limosyl Lactobacillus fermentum LM1004 dead cells 1×10 8 cell / mL)8.66±1.22-9LSD +LM1020_14.27±1.88-10.04510LSD +LM1020_211.96±0.340.45911LSD+LM1020_36.21±0.71-1.2134
[0147] 1) Predicted value calculation formula = predicted value calculated using Colby's formula
[0148] Manufacturing Example 1. Development of a liquid formulation containing heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0149] In Example 5 above, a liquid formulation was developed that can be evenly applied by spraying on the scalp, containing the effective ingredients of hair loss alleviation functional cosmetics, L-menthol, salicylic acid and dexpanthenol, which have been confirmed to have a synergistic effect, and heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020. The developed liquid formulation contains 0.3% L-menthol, 0.26% salicylic acid, 0.2% dexpanthenol, and 5% heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020, and other ingredients include purified water, ethanol, Alanine / Histidine / Lysine Polypeptide Copper HCl, polyacrylate crosspolymer-6, coconut acid, proline, tea tree oil, glycerin, peptide, butylene glycol, 1,2-hexanediol, green tea extract, lavender flower extract, quince extract, and ethylhexanediol.
[0150] Example 8. Verification of hair loss relief effect through human application test
[0151] The human clinical trial was conducted by Global Medical Research Center, Inc., and received approval from the Research Ethics Committee (Approval Number: GIRB-21029-ET). Twenty-five Korean men and women, aged 18 to 54, participated in the trial, of which two dropped out.
[0152] All participants applied the product of Preparation Example 1 evenly to the scalp before going to bed for 6 months, and visited at intervals of 0, 8, 16, and 24 weeks to evaluate product compliance, hair density measurement using phototrichogram, visual evaluation by experts, and efficacy questionnaire evaluation of participants (satisfaction with hair growth, satisfaction with hair loss relief, and satisfaction with the frontal hairline).
[0153] As a result of investigating the compliance of the test subjects with the product, it was confirmed that there were '0' test subjects who used the product less than 80% of the time based on the number of uses. Therefore, all participants used the test product as prescribed, once a day, before going to bed, by applying it to the scalp for a total of 24 weeks of the test period.
[0154] The efficacy of the test product was verified through hair density measurement (phototrichogram), photography and visual evaluation by experts, and effectiveness evaluation of user satisfaction. To measure hair density, a 1 cm area of hair loss was measured. 2 After shaving in a circular shape, a 1 mm diameter dot was tattooed and photographed using a hair density meter. Hair density was measured every 8 weeks for a total of 4 times, and 1 cm from the tattoo was used as a reference. 2 The number of hairs within the circle was measured.
[0155] As a result, the test participants showed a continuous increase in hair density compared to before using the test product, and after 16 weeks, the hair density increased statistically significantly compared to before use (p<0.05).
[0156] Change in hair density during the test period (n / cm) 2 )Hair density (n / cm) 2 )0 weeks 133.696±24.69 78 weeks 137.739±24.58 84.04 316 weeks 139.609±24.95 45.91 324 weeks 140.870±24.78 17.174 Within-group comparison significance probability (p-value) 8 weeks 1.000 16 weeks 0.019 24 weeks 0.002
[0157] The visual evaluation by experts was conducted by photographing the test areas, the crown (90°) and the frontal hairline (45°). The visual evaluation was conducted by two experts, and the changes were rated on a 7-point scale. As a result, the test participants were able to see that their hair loss symptoms were alleviated and hair growth was progressing to a degree that was visible to the naked eye while using the test product. The degree of agreement between researchers in the visual evaluation was confirmed using the ICC (Intraclass Correlation Coefficients) method to verify the precision of the research results. The intraclass correlation coefficient between researchers was 0.916, which is close to 1, indicating perfect agreement.
[0158] Usage period Test group Evaluator 1 Evaluator 2 Visual evaluation score 0 weeks 0.000±0.0000.000±0.0008 weeks 0.043±0.2090.087±0.28816 weeks 0.261±0.5410.261±0.54124 weeks 0.261±0.5410.217±0.518
[0159] After using the product, the efficacy questionnaire of the test participants was evaluated on a 7-point scale (-3 points: very worse, -2 points: worse, -1 point: slightly worse, 0 points: no change, 1 point: slightly better, 2 points: better, 3 points: very better). As a result, the participants who used the test product for a total of 24 weeks were satisfied with hair growth, hair loss reduction, and frontal hairline, and the satisfaction tended to increase as the period of use increased.
[0160] Satisfaction with hair growth in the test group during the usage period: 8 weeks 0.913±0.848 16 weeks 1.435±0.788 24 weeks 1.271±0.600
[0161] Satisfaction with hair loss relief in the test group during the usage period: 8 weeks 1.174±0.778 16 weeks 1.304±0.70 324 weeks 1.522±0.730
[0162] Satisfaction with the front hairline of the test group during the usage period 8 weeks 0.609±0.783 16 weeks 1.217±0.795 24 weeks 1.217±0.902
[0163] Example 9. Changes in the scalp microbiota environment before and after using a product containing heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020.
[0164] The scalp microbial environment before and 24 weeks after using the product of Manufacturing Example 1 was compared. Scalp microbiota was collected using sterilized skin-microbiome collection swabs, and immediately after collection, the samples were stored at low temperature using nucleic acid transport medium and sent to a microbiological analysis institute. The scalp microbiota was analyzed by sequencing, creating a library, and performing 16S metagenome analysis for comparison.
[0165] As a result, the test participants showed a four-fold increase in scalp lactic acid bacteria after using the product of Manufacturing Example 1 (Fig. 7a). In addition, the diversity of scalp microorganisms also improved, with a 60% increase in total scalp microbial diversity (Fig. 7b) and a 176% increase in scalp lactic acid bacteria diversity (Fig. 7c). After using the product of Manufacturing Example 1, Staphylococcus caprae, a microorganism that decreases in people with alopecia areata, tended to increase (Figs. 7d and 7e). Therefore, it was confirmed that applying the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 to the scalp can prevent hair loss symptoms by changing the scalp microbial environment.
[0166] The above description of the present invention is for illustrative purposes only, and those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single entity may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined manner.
[0167]
Claims
1. A cosmetic composition for the proliferation of breast papilla cells, comprising heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
2. In paragraph 1, A cosmetic composition for the proliferation of breast papilla cells, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 is derived from fermented dough.
3. In paragraph 1, A cosmetic composition for proliferation of breast papilla cells, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 has a ratio of saturated fatty acid: unsaturated fatty acid: cyclic fatty acid of 0.1 to 2: 0.25 to 5: 0.03 to 0.
6.
4. In paragraph 1, A cosmetic composition for the proliferation of breast papilla cells, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 increases the expression of CDK2, CDK4, cyclin B1 and cyclin D1.
5. In paragraph 1, A cosmetic composition for proliferation of breast papilla cells, wherein the heat-treated lactic acid bacteria Rimosylactobacillus fermentum LM1020 reduces the expression level of the 5α-reductase-1 gene and increases the expression levels of the FGF7, FGF10, and EGF genes.
6. In paragraphs 1 to 5, A cosmetic composition for proliferation of breast papilla cells, wherein the cosmetic composition further comprises L-menthol, salicylic acid and dexpanthenol.
7. In paragraph 6, The above heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 is 1×10 6 cell / mL or 1×10 7 A cosmetic composition for proliferation of breast papilla cells, the composition comprising cells / mL.
8. In paragraph 6, The cosmetic composition for proliferation of the above-mentioned hair follicle cells further comprises purified water, ethanol, Alanine / Histidine / Lysine Polypeptide Copper HCl, polyacrylate crosspolymer-6, coconut acid, proline, tea tree oil, glycerin, peptide, butylene glycol, 1,2-hexanediol, green tea extract, lavender flower extract, quince extract, and ethylhexanediol.
9. In paragraph 8, The cosmetic composition for proliferation of the above-mentioned hair follicle cells is a cosmetic composition for proliferation of hair follicle cells that increases the diversity of microorganisms and lactic acid bacteria of the scalp.
10. A food composition for proliferation of breast milk papilla cells containing heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
11. In paragraph 10, A food composition for the proliferation of breast milk papilla cells, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 is derived from fermented dough.
12. In paragraph 10, The above heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 is a food composition for proliferation of breast papilla cells, wherein the ratio of saturated fatty acid: unsaturated fatty acid: cyclic fatty acid is 0.1 to 2: 0.25 to 5: 0.03 to 0.
6.
13. A pharmaceutical composition for treating hair loss comprising heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 (KCCM12918P) as an active ingredient.
14. In paragraph 13, A pharmaceutical composition for treating hair loss, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 is derived from fermented dough.
15. In paragraph 13, A pharmaceutical composition for treating hair loss, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 has a ratio of saturated fatty acid: unsaturated fatty acid: cyclic fatty acid of 0.1 to 2: 0.25 to 5: 0.03 to 0.
6.
16. In paragraph 13, A pharmaceutical composition for treating hair loss, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 increases the expression of CDK2, CDK4, cyclin B1 and cyclin D1.
17. In paragraph 13, A pharmaceutical composition for treating hair loss, wherein the heat-treated lactic acid bacteria Rimosyl Lactobacillus fermentum LM1020 reduces the expression level of the 5α-reductase-1 gene and increases the expression levels of the FGF7, FGF10, and EGF genes.
Citation Information
Patent Citations
Lactobacillus fermentum stain for preventing depilation, improving hair growth or improving sexual disfunction, and composition comprising the same
KR101791088B1
Cosmetic composition for prevention of depilation and improvement of hair growth having fermented peptone having activator of dermal papilla cell and geminal matrix cell, and formulation having the same
KR1020150072327A
Composition comprising lactic acid bacteria derived extracellular vesicles for preventing hair loss or promoting hair growth
KR1020170038462A
Smartphone recovery phone key
KR1020240164986A
Composition for preventing hair loss and promoting hair growth comprising postbiotic components from heat-treat limosilactobacillus fermentum LM1020
KR102578662B1
